DrugInfoSys

Palivizumab

Drug #1736

Palivizumab is a monoclonal antibody used for the prevention of respiratory syncytial virus infection in infants at high risk of infection.

← Previous drugNext drug →

Primary Characteristics

Non-proprietary name: Palivizumab.

Molecular structure of Palivizumab

Pharmacokinetics

None recorded.

Advertisement

Indications

Palivizumab is primarily indicated in conditions like Duodenal errosions.

Contraindications

None recorded.

Dosage

Palivizumab's dosage details are as follows:

DoseSingle DoseFrequencyRouteInstructions
Adult Dosage
15 mg/kg of body weight15 mg/kg of body weight—IM
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

None recorded.

Side Effects

Palivizumab is known to cause more or less tolerable side effects which are usually transient. These include Abnormal LFT, Cough , Diarrhea, Fever, Injection-site reactions, Leucopenia, Nervousness, Pain , Rashes , Rhinitis , Vomiting , Wheezing .

Warnings / Precautions

Palivizumab should be used with caution in moderate to severe acute infection or febrile illness; congenital heart disease; thrombocytopenia. Facilities for cardiopulmonary resuscitation must be at hand.

Available Brands

None recorded.

Drug Classification

  1. 1.17.12 — Other alimentary tract preparations